Algeta appoints senior vp, Protein Therapeutics
New role created to drive development of Thorium platform
Abrahmsen takes responsibility for the development of Oslo-based Algeta’s Thorium platform and for building and overseeing the preclinical development of a pipeline of alpha-pharmaceutical candidates based on tumour-targeted thorium-227 conjugates.
This builds on the progress made with Alpharadin, an alpha-pharmaceutical being developed in a phase III trial by Algeta and Bayer Schering Pharma for treating bone metastases arising from castration-resistant prostate cancer.
Abrahmsen has joined Algeta from Affibody, a Swedish company developing proprietary targeting molecules for therapeutic and diagnostic purposes, where he held the position of chief scientific officer since 2004. Prior to this he worked for Genentech and Pharmacia, where he established their phage display and antibody cloning capabilities.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027